Premium
Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes
Author(s) -
Worel Nina,
Frank Nelli,
Frech Christian,
Fritsch Gerhard
Publication year - 2017
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.14182
Subject(s) - plerixafor , cd34 , apheresis , cd38 , immunology , progenitor cell , lymphocyte , granulocyte colony stimulating factor , leukapheresis , haematopoiesis , medicine , stem cell , andrology , cancer research , chemotherapy , oncology , biology , cxcr4 , chemokine , platelet , immune system , microbiology and biotechnology
BACKGROUND Peripheral blood stem cells mobilized with granulocyte–colony‐stimulating factor (G‐CSF) with or without chemotherapy are routinely used for autologous hematopoietic cell transplantation. Plerixafor, a chemokine‐receptor inhibitor, increases the amount of circulating CD34+ cells and improves harvest results. However, limited information is available regarding the composition of apheresis products with respect to CD34+ and lymphocyte subtypes collected after various mobilization regimens. STUDY DESIGN AND METHODS We used a recently established single‐platform multicolor flow‐cytometric analysis including CD45RA and CD133 to define CD34+ subpopulations and lymphocyte subsets in products obtained either after G‐CSF with or without chemotherapy alone (G, n = 40) or with addition of plerixafor (GP, n = 40). RESULTS Absolute numbers of white blood cells and lymphocyte subtypes were significantly higher after plerixafor, which was not observed for absolute CD34+ counts. However, distinct differences in terms of CD34+ subtypes were observed. The most primitive multipotent progenitors (CD45RA–CD133+CD34+CD38 low ) predominated significantly after G (median, 49.2%; range, 15.2%‐63%) compared to GP (median, 34.4%; range, 12%‐62%; p < 0.001), whereas more differentiated subsets clearly prevailed after GP. CONCLUSION In contrast to the findings of other authors, our study shows a clear shift toward more committed CD34+ subsets after plerixafor in poor mobilizers and elucidates the importance of informative surface markers like CD45RA and CD133 in addition to CD38 to discriminate earlier from more committed CD34+ cells. Further studies are needed to analyze whether these findings have an impact on clinical outcome.